Mesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions

Reuters11-07

<a href="https://laohu8.com/S/MLAB">Mesa Laboratories</a> Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions

Mesa Laboratories Inc. reported fiscal year 2025 revenues of $241 million, reflecting a five-year compound annual growth rate $(CAGR)$ of 15.4%. The company's fiscal year 2025 gross profit margin was 62.6%, with an adjusted operating income margin of 23.5%. High growth verticals, including biopharmaceuticals, medical devices, and genomics, expanded their share of the portfolio from 50% to 69% over the past five years. Mesa Laboratories operates across several divisions, with fiscal year 2025 revenues as follows: Clinical Genomics ($47.1 million), Biopharmaceutical Development ($48.7 million), Calibration Solutions ($51.8 million), and Sterilization & Disinfection Control ($93.4 million). The company highlighted its ongoing focus on core organic revenue growth and operational improvements within regulated markets. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581456460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581456460","market":"us","top_or_hot":-1,"title":"Mesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLAB\">Mesa Laboratories</a> Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mesa Laboratories Inc. reported fiscal year 2025 revenues of $241 million, reflecting a five-year compound annual growth rate <a href=\"https://laohu8.com/S/CAGR\">$(CAGR)$</a> of 15.4%. The company's fiscal year 2025 gross profit margin was 62.6%, with an adjusted operating income margin of 23.5%. High growth verticals, including biopharmaceuticals, medical devices, and genomics, expanded their share of the portfolio from 50% to 69% over the past five years. Mesa Laboratories operates across several divisions, with fiscal year 2025 revenues as follows: Clinical Genomics ($47.1 million), Biopharmaceutical Development ($48.7 million), Calibration Solutions ($51.8 million), and Sterilization &amp; Disinfection Control ($93.4 million). The company highlighted its ongoing focus on core organic revenue growth and operational improvements within regulated markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLAB\">Mesa Laboratories</a> Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mesa Laboratories Inc. reported fiscal year 2025 revenues of $241 million, reflecting a five-year compound annual growth rate <a href=\"https://laohu8.com/S/CAGR\">$(CAGR)$</a> of 15.4%. The company's fiscal year 2025 gross profit margin was 62.6%, with an adjusted operating income margin of 23.5%. High growth verticals, including biopharmaceuticals, medical devices, and genomics, expanded their share of the portfolio from 50% to 69% over the past five years. Mesa Laboratories operates across several divisions, with fiscal year 2025 revenues as follows: Clinical Genomics ($47.1 million), Biopharmaceutical Development ($48.7 million), Calibration Solutions ($51.8 million), and Sterilization &amp; Disinfection Control ($93.4 million). The company highlighted its ongoing focus on core organic revenue growth and operational improvements within regulated markets. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5mYvR9:1","article_id":"2581456460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581456460","pubTimestamp":1762465520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions. Mesa Laboratories Inc. reported fiscal year 2025 revenues of $241 million, reflecting a five-year compound annual growth rate  of 15.4%. The company's fiscal year 2025 gross profit margin was 62.6%, with an adjusted operating income margin of 23.5%. High growth verticals, including biopharmaceuticals, medical devices, and genomics, expanded their share of the portfolio from 50% to 69% over the past five years. Mesa Laboratories operates across several divisions, with fiscal year 2025 revenues as follows: Clinical Genomics , Biopharmaceutical Development , Calibration Solutions , and Sterilization & Disinfection Control . The company highlighted its ongoing focus on core organic revenue growth and operational improvements within regulated markets. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Techno","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","MLAB":"Mesa Laboratories","BK4121":"生命科学工具和服务"},"translate_title":"Mesa Laboratories Inc.发布投资者演示文稿，强调生命科学工具和质量控制解决方案的增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLAB":0.9},"content_text":"Mesa Laboratories Inc. unveils investor presentation highlighting growth in life sciences tools and quality control solutions\n    \n\n        Mesa Laboratories Inc. reported fiscal year 2025 revenues of $241 million, reflecting a five-year compound annual growth rate $(CAGR)$ of 15.4%. The company's fiscal year 2025 gross profit margin was 62.6%, with an adjusted operating income margin of 23.5%. High growth verticals, including biopharmaceuticals, medical devices, and genomics, expanded their share of the portfolio from 50% to 69% over the past five years. Mesa Laboratories operates across several divisions, with fiscal year 2025 revenues as follows: Clinical Genomics ($47.1 million), Biopharmaceutical Development ($48.7 million), Calibration Solutions ($51.8 million), and Sterilization & Disinfection Control ($93.4 million). The company highlighted its ongoing focus on core organic revenue growth and operational improvements within regulated markets. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesa Laboratories Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581456460","isCrawlerRequest":true}